Pancrelipase protease

Generic Name: Pancrelipase protease

Brand Names: Cotazym, Creon, Pancrease MT, Pancreaze, Pertzye, Viokace, Zenpep

Drug Type: Biotech

CAS Number: 9001-94-9

Unique Ingredient Identifier: 3560D81V50

Background: Pancrelipase, in general, is composed of a mixture of pancreatic enzymes which include amylases, lipases, and proteases. These enzymes are extracted from porcine pancreatic glands. The pancrelipase protease is a mix of enzymes, formed by trypsin and chymotrypsin, that proteolytically cleave peptide bonds and are involved in food digestion. The pancrelipase mixture, including pancrelipase protease, was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010.

Indication: Please refer to Pancrelipase.

Associated Conditions: Exocrine Pancreatic Insufficiency

Clinical Trials

Interaction With HIV Antiretroviral Agents

Phase 1

Completed

Conditions: HIV-DDI

Interventions: Drug: Riociguat (Adempas, BAY 63-2521)
Drug: TRIUMEQ
Drug: STRIBILD
Drug: Antiretroviral protease inhibitor
Drug: ATRIPLA
Drug: COMPLERA

First Posted Date: 2015-09-22

Last Posted Date: 2017-12-06

Lead Sponsor: Bayer

Target Recruit Count: 40

Registration Number: NCT02556268

Management of Participants With Low-level Persistent Viremia (ANRS 161 L-VIR)

Phase 3

Terminated

Conditions: HIV-1 Infection
Treatment Resistant Disorders
Viremia

Interventions: Drug: Protease inhibitor
Drug: Isentress® (raltegravir)
Other: Counseling arm

First Posted Date: 2014-09-25

Last Posted Date: 2015-10-12

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 4

Registration Number: NCT02247687

Locations: 🇫🇷
Hôpital Européen Georges Pompidou, France, France
🇫🇷
Hôpital Avicenne, Bobigny, France
🇫🇷
Hôpital Jean Verdier, Bondy, France

and more 17 locations

Multicentre Study To Assess Changes In Bone Mineral Density Of The Switch From Protease Inhibitors To Dolutegravir In HIV-1-Infected Subjects With Low Bone Mineral Density

Phase 3

Completed

Conditions: HIV-1 Infection

Interventions: Drug: Dolutegravir, 50mg every 24 hours
Drug: Protease Inhibitor/ritonavir

First Posted Date: 2013-10-22

Last Posted Date: 2015-11-30

Lead Sponsor: Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

Target Recruit Count: 75

Registration Number: NCT01966822

Locations: 🇪🇸
GermansTrias i Pujol Hospital, Badalona, Barcelona, Spain
🇪🇸
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
🇪🇸
Hospital Clínico San Carlos, Madrid, Spain

Influence of Nevirapine on HCV Viral Load

Not Applicable

Conditions: HCV Infection.
HCV Viral Load.

Interventions: Drug: Nevirapine
Drug: efavirenz, protease inhibitors

First Posted Date: 2011-01-17

Last Posted Date: 2011-01-17

Lead Sponsor: Valme University Hospital

Target Recruit Count: 60

Registration Number: NCT01277627

Locations: 🇪🇸
Valme University Hospital, Seville, Spain

Raltegravir Switch Study to Reduce Liver Fibrosis Progression in HIV-Hepatitis C Co-infection

Phase 2

Completed

Conditions: HIV
Hepatitis C
Liver Fibrosis

Interventions: Drug: Raltegravir
Drug: Ritonavir-boosted protease inhibitor

First Posted Date: 2010-11-01

Last Posted Date: 2016-09-21

Lead Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre

Target Recruit Count: 9

Registration Number: NCT01231685

Locations: 🇨🇦
Montreal Chest Institute, Montreal, Quebec, Canada
🇨🇦
Providence Health Care- St. Paul's Hospital, Vancouver, British Columbia, Canada
🇨🇦
University Health Network - Toronto General Hospital Division, Toronto, Ontario, Canada

Protease Inhibitor Monotherapy Versus Ongoing Triple-therapy in the Long Term Management of HIV Infection (PIVOT)

Phase 4

Conditions: HIV Infection
Acquired Immunodeficiency Syndrome

Interventions: Drug: Protease Inhibitor
Drug: Standard-of-care Antiretroviral therapy

First Posted Date: 2010-10-29

Last Posted Date: 2012-10-10

Lead Sponsor: Medical Research Council

Target Recruit Count: 587

Registration Number: NCT01230580

A Study With TMC125 in Human Immunodeficiency Virus (HIV) Type 1 Infected Patients, Who Were Treated With TMC125 Arm in a Sponsor-Selected TMC125 Study

Phase 2

Completed

Conditions: Human Immunodeficiency Virus Type 1

Interventions: Drug: Etravirine (ETR)
Drug: Nucleotide reverse transcriptase inhibitors (NRTIs)
Drug: Protease inhibitors (PIs)
Drug: Enfuvirtide (ENF)

First Posted Date: 2005-08-10

Last Posted Date: 2013-06-20

Lead Sponsor: Tibotec Pharmaceuticals, Ireland

Target Recruit Count: 211

Registration Number: NCT00128830

Evaluation of the Occurrence of Lipoatrophy in HIV-1 Infected Naive Patients

Phase 4

Terminated

Conditions: HIV-Associated Lipodystrophy Syndrome
HIV Infections

First Posted Date: 2005-07-22

Last Posted Date: 2005-11-15

Lead Sponsor: French National Agency for Research on AIDS and Viral Hepatitis

Target Recruit Count: 112

Registration Number: NCT00122668

Locations: 🇫🇷
Service des Maladies infectieuses et Tropicales Hopital Pitie Salpetriere, Paris, France

Study Evaluating the Impact on Fat Distribution of Nucleoside Reverse Transcriptase Inhibitor (NRTI)-Sparing Regimens in Antiretroviral Experienced Patients With Lipoatrophy

Phase 4

Terminated

Conditions: HIV Infections
HIV Lipodystrophy Syndrome

First Posted Date: 2005-07-22

Last Posted Date: 2005-11-15

Lead Sponsor: French National Agency for Research on AIDS and Viral Hepatitis

Target Recruit Count: 100

Registration Number: NCT00122655

Locations: 🇫🇷
Service des Maladies infectieuses et Tropicales Hopital Pitie Salpetriere, Paris, France

Dose Ranging Trial of Tipranavir/Ritonavir in Treatment-Experienced HIV Infected Individuals

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2002-05-03

Last Posted Date: 2005-09-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 165

Registration Number: NCT00034866

Locations: 🇺🇸
University of So. California / LA County USC Medical Center, Los Angeles, California, United States
🇺🇸
Atlanta VA Medical Center, Dept. of ID, Decatur, Georgia, United States
🇺🇸
CORE Center, Cook County Hospital, Chicago, Illinois, United States

and more 46 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy